Mallika Dhawan, MD
Assistant Clinical Professor
Medicine
School of Medicine

She is an assistant professor working in the P1 or Experimental Therapeutics clinic for patients with advanced cancers and also specializes in the prevention and treatment of hereditary cancer syndromes in the Center for BRCA Research. Her research interests are focused on tumors with mutations in homologous recombination, novel drug targets and preventative measures for inherited cancer predisposition syndromes.

• Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers.
  Communications biology 2022 Hakkaart C, Pearson JF, Marquart L, Dennis J, Wiggins GAR, Barnes DR, Robinson BA, Mace PD, Aittomäki K, Andrulis IL, Arun BK, Azzollini J, Balmaña J, Barkardottir RB, Belhadj S, Berger L, Blok MJ, …
• A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies.
  Cancer research communications 2022 Tsang ES, Aggarwal RR, Dhawan MS, Bergsland EK, Alvarez EA, Calabrese S, Pacaud R, Garcia J, Fattah D, Thomas S, Grabowsky J, Moasser MM, Munster PN
• Implementation of an Embedded In-Clinic Genetic Testing Station to Optimize Germline Testing for Patients with Pancreatic Adenocarcinoma.
  The oncologist 2021 Walker EJ, Goldberg D, Gordon KM, Pedley C, Carnevale J, Cinar P, Collisson EA, Tempero MA, Ko AH, Blanco AM, Dhawan M
• The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant.
  Genetics in medicine : official journal of the American College of Medical Genetics 2021 Lakeman IMM, van den Broek AJ, Vos JAM, Barnes DR, Adlard J, Andrulis IL, Arason A, Arnold N, Arun BK, Balmaña J, Barrowdale D, Benitez J, Borg A, Caldés T, Caligo MA, Chung WK, Claes KBM, GEMO Study …
• Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer.
  Cancer 2021 Kwon DH, Chou J, Yip SM, Reimers MA, Zhang L, Wright F, Dhawan MS, Borno HT, Desai A, Aggarwal RR, Wyatt AW, Small EJ, Alva AS, Chi KN, Feng FY, Koshkin VS
• Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC.
  JCO oncology practice 2020 Szymaniak BM, Facchini LA, Giri VN, Antonarakis ES, Beer TM, Carlo MI, Danila DC, Dhawan M, George D, Graff JN, Gupta S, Heath E, Higano CS, Liu G, Molina AM, Paller CJ, Patnaik A, Petrylak DP, …
• Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer.
  Nature communications 2020 Terranova-Barberio M, Pawlowska N, Dhawan M, Moasser M, Chien AJ, Melisko ME, Rugo H, Rahimi R, Deal T, Daud A, Rosenblum MD, Thomas S, Munster PN
• Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.
  European urology 2019 Reimers MA, Yip SM, Zhang L, Cieslik M, Dhawan M, Montgomery B, Wyatt AW, Chi KN, Small EJ, Chinnaiyan AM, Alva AS, Feng FY, Chou J
• BRCAness and prostate cancer: diagnostic and therapeutic considerations.
  Prostate cancer and prostatic diseases 2018 Dhawan M, Ryan CJ
• Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.
  Breast cancer research : BCR 2017 Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, …
• Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2017 Dhawan MS, Bartelink IH, Aggarwal RR, Leng J, Zhang JZ, Pawlowska N, Terranova-Barberio M, Grabowsky JA, Gewitz A, Chien AJ, Moasser M, Kelley RK, Maktabi T, Thomas S, Munster PN
• A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study.
  Urologic oncology 2017 Aggarwal R, Bryce A, Ryan CJ, Harzstark A, Derleth C, Kim W, Friedlander T, Lin AM, Rodvelt-Bagchi T, Dhawan M, Zhang L, Lee M, Siebeneck E, Hough J, Small EJ
• Utility of novel androgen receptor therapies in the real world: A nuanced approach.
  Urologic oncology 2016 Dhawan M, Ryan CJ
• DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.
  The oncologist 2016 Dhawan M, Ryan CJ, Ashworth A
• Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.
  Clinical genitourinary cancer 2015 Zhang T, Dhawan MS, Healy P, George DJ, Harrison MR, Oldan J, Chin B, Armstrong AJ
• Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors.
  Hypertension (Dallas, Tex. : 1979) 2010 Robinson ES, Khankin EV, Choueiri TK, Dhawan MS, Rogers MJ, Karumanchi SA, Humphreys BD
• Incidence and prevention of intervertebral cage overhang with minimally invasive lateral approach fusions.
  Spine 2010 Regev GJ, Haloman S, Chen L, Dhawan M, Lee YP, Garfin SR, Kim CW
• Morphometric analysis of the ventral nerve roots and retroperitoneal vessels with respect to the minimally invasive lateral approach in normal and deformed spines.
  Spine 2009 Regev GJ, Chen L, Dhawan M, Lee YP, Garfin SR, Kim CW